Brazil’s laws

Biotechnology development in Brazil is moving, but slowly, due to the lack of (1) investments from the private sector and (2) a clear and consistent exercise of the Brazilian patent law (9279/96). In this commentary we will deal with the first issue and in the next with the patent context.

Science in Brazil has progressed considerably in the last couple of decades. Science output in Brazil was multiplied by five since 1980 and Brazil contributes close to 3% to the world scientific output.

blue green.bmp

Figure 1 – Brazilian scientific output with respect to the world (indexed by Thomson/ISI), and to Latin America from 1981-2008. In green: Brazilian output with respect to the world. In blue: Brazilian output with respect to Latin America.

When we compare the public investment made in Brazil to the same public investments made by developed countries the numbers are similar. However private investments are far from what one can see in the same developed countries. For this reason, combined Brazil invests slightly above 1.0% of its GNP in science and technology.

blue yellow.bmp

Figure 2 – Public and private investments in science and technology by country as % of the GDP. Public (yellow) Private (blue)

Brazil established recently two laws to stimulate private investments. The Innovation Law, December 2, 2004, and the Good Law, November 21, 2005. The last one was complemented by a Decree, on June 7, 2006, which in chapter III Articles 17 to 26 states that those entrepreneurs active in technological research and innovation can automatically deduct this investment from the income tax. In summary the government renounces to receive the tax as long as the money is invested in technological development and innovation. Both laws are recent and the results, although moving up, are still modest. In 2006 private companies invested 0.09% of the GNP.

In 2008 these investments climbed to 0.3 % of the GNP. The number of private companies in 2006 was 131 and the fiscal incentive US$1.4 billion. In 2009, 635 companies deducted from their fiscal taxes US$5 billion.

There are flaws: entrepreneurs complain that calculations are complicated (services are now available to help) and they fear that when they submit their deduction proposal the financial system will contest what they presented as technological development or innovation. Another flaw is that the laws do not benefit nascent and small companies – in other words, companies typical of the biotech sector. For this reason few biotech companies (particularly in the area of health) are benefited. Risk capital to move up small companies is still a problem in the biotech sector. Brazil has supported these small companies through another mechanism (I’ll discuss it later). The system helps these companies but they hardly are funded to scale up their business.

Luiz Antonio Barreto de Castro

No Genes, No Future

future2.jpg

The biotech industry relies strongly on genetic engineering, and on genes being characterized and properly expressed. This was clear to me more than three decades ago, after Herbert Boyer expressed in California the insulin gene in E. coli. I’m a member of the Brazilian Academy of Science, and since the ‘80s, I’ve stated that countries that do not identify genes will never build a competitive pharmaceutical industry, or agbusiness industry, or, more recently, biofuels industry.

Well, Brazil does not have its genes, as they say. And its pharmaceutical industry has accumulated a US$7 billion debt, when comparing sales to importing. The genes coding for the enzymes capable of converting cellulose to ethanol will come from large corporations, such as Novozymes, Amyris and Ceres – all of which are already working in Brazil, benefiting from its sugar cane industry. Monsanto acquired Alellyx and CanaVialis, both related to sugar cane.

Because it’s important for Brazil that the best technology reaches consumers, I do not criticize that. Good partners are of course welcome. The problem is that when we move to agriculture, Brazil does not have a clear strategy to identify and use the genes needed for the plants of the future. Nevertheless Brazil is second in genetically modified organisms (GMOs) cultivated, behind only the US. So what is the problem? The price we have to pay for the genes.

The RR gene from Monsanto, for making plants tolerant to glyphosate, last year cost Brazil US$200 million for our soybean farmers. That weakens Brazilian competitiveness. Other necessary plant genes are in the hands of the large corporations. We can imagine that Brazil won’t be able to compete with China in the cotton business unless Brazil does not need to pay for the genes to the Bt technology. China has its own Bt genes, after all.

Fortunately for Brazil, we have a unique Bt gene toxic to Boll weevil, coming from Embrapa, the Brazilian Agriculture Research Corporation. Boll weevil costs to the cotton farmer $150 per hectare. EMBRAPA has a rich Bt collection with 4,000 mutants, and other Bt genes may be there. But it begs the question: Why doesn’t Brazil have the genes to build the pharmaceutical industry?

Laws, in effect prevent scientists from finding these genes in our own biodiversity – a problem that has existed since 2000 and controlled by the Ministry of Environment. There is a council called CGEN, but it does not operate. It is so prohibitive, it prevents The Butanta Institute from working with its own snakes (which they have being doing for more than a century), unless authorized by this law. Institutes like Vital Brasil, in business for more than century, suffer from the same fate. More than a hundred cases are suing scientists and institutions for collecting plants without authorization from the Brazilian Institute for the Environment and Renewable Natural Resources (IBAMA) – the right arm for the law. Even though he was authorized, researcher Elibio Rech, from EMBRAPA, was fined 100,000 reais (US$45,000) because he developed a technology from a spider web coding gene. He’s allowed to do the science, but not develop a technology. Then what is Brazil’s famous biodiversity good for?

This never happened, of course, with the Canadian Air Force, which has used this spider gene for more than a decade. The law (called a provisional measure) has been a disaster for the Brazilian biotech industry. We tried to get a new law passed for the past 10 years, but never succeeded. Brazil cannot waste more time. Will we develop the Bt genes? Who knows. The matter should move from the hands of the Ministry of the Environment, to the hands of the Ministry of Science and Technology, which previously had control of such matters through the National Council of Research – all of which was before the Biodiversity Convention and before the passing of the provisional measure just mentioned.

What do I think should happen to the provisional measure? It should disappear, legally. It is judicially possible for this to happen.

Luiz Antonio Barreto de Castro

Brazil Feeds the World

brazil flag1.JPG

Brazil produces almost 150 million tons of grain in 50 million hectares, and it multiplied grain production by four in the last four decades. It can double again that figure without destroying the Amazon or the Cerrado. Here’s how.

This started in 1965, when Brazil established its first law to regulate the commercialization of seeds. When the Brazilian Enterprise for Agricultural Research (EMBRAPA) was created in the mid seventies, Brazil started training plant cell, molecular, and developmental biologists. Then Sectoral Funds were created in the ’90s for areas such as biotechnology and agribusiness. Without those developments, the seed industry would not have flourished in Brazil, and this industry was essential for biotech crops later developed.

When Herbert Boyer expressed an insulin gene in bacteria, I was a freshman PhD student studying plant physiology at UC-Davis, being funded by EMBRAPA. That achievement alerted us that the world was going to change. Genetic engineering was the most important science discovery, after the genetic code itself.

When I returned to Brazil, I was hired by EMBRAPA in 1981 to build agricultural biotechnology at a research center called CENARGEN in Brasilia. It was eventually named the National Research Center for Genetic Resources and Biotechnology. At this point, not one plant had been engineered, and when, in 1985, Brazilian scientists visited Europe to discuss biotech, we had nothing to offer.

Twenty-five years later when we came back to the same institutions, everything had been modified. Now we can express any gene of any organism in plants, and plant molecular biologists team up with plant breeders to create plants for the tropics. When the necessary genes are not available, we settle partnerships with gene companies. Also, EMBRAPA established the Foundation Seed Program, inspired by the US system, and this offers transgenic seeds to companies, big and small. This means that even small companies can compete if the quality of the seed is good.

Scientists in Brazil in the future hope to make grasses that fix nitrogen, so that poor people do not have to buy urea to use as chemical fertilizer, which pollutes the soil and the water. EMBRAPA scientists will release the first green beans engineered to become resistant to the Golden Mosaic Virus, using RNA interference technology.

Few countries made use of the gene revolution, particularly as related to developmental biology, to advance agriculture as we did in Brazil. We verified that genes do not have to be transferred as transgenics require, because genes are common to all species. The strategy is to release genes, such as the anti-fungic dermaseptin peptides found in frogs, to work as anti-fungic peptides in soybeans. This concept is called intragenic by Carlos Bloch, a scientist from EMBRAPA, which today is the largest of its kind, with offices in the five continents.

That’s solid progress, but the question is, why did it take so long to see biotech crops released in Brazil? We had a biosafety law in operation since 1995, but literally lost 10 years disputing the judiciary in Brazil, which took sides and made political decisions against science and scientists.

After 2005 everything changed. A new biosafety law stimulated the combination of tropical genetics and biotech so much that Brazil is second only to the US in biotech crop production. We have few plants entirely engineered in Brazil, but Brazilian corporations take advantage of our breeders’ expertise and release the best crops for all Brazilian biomes. Still, the gene revolution has not resolved a few important things.

We still have not produced plants that can defend themselves against bacteria and fungi. This technology is available in the US and at the Fraunhofer Institute in Germany. Few institutions have reliable genes to generate plants resistant to drought and to soil aluminum toxicity that together affects more than 80% of tropical soils.

There is work to do, but Brazil can make the gene revolution work in the same direction as the green revolution did decades ago, by the hands of Norman Borlaug with more powerful science tools available. 

Luiz Antonio Barreto de Castro